PDS Biotechnology (PDSB) Cash & Equivalents (2014 - 2026)

PDS Biotechnology (PDSB) has 12 years of Cash & Equivalents data on file, last reported at $26.7 million in Q4 2025.

• Quarterly Cash & Equivalents fell 35.93% year-over-year to $26.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $26.7 million (down 35.93% YoY) and the FY2025 annual result came in at $26.7 million, down 35.93% from the prior year.
• Cash & Equivalents grew to $26.7 million in Q4 2025, from $26.2 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $74.7 million in Q2 2021 to a low of $25.0 million in Q1 2021.
• A 5-year average of $53.5 million and a median of $57.1 million in 2023 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2021 — Cash & Equivalents jumped 341.4% — and 2025, when it plunged 47.39%.
• Tracing PDSB's Cash & Equivalents over 5 years: stood at $65.2 million in 2021, then increased by 13.15% to $73.8 million in 2022, then retreated by 23.38% to $56.6 million in 2023, then fell by 26.29% to $41.7 million in 2024, then tumbled by 35.93% to $26.7 million in 2025.
• The last three Cash & Equivalents figures came in at $26.7 million (Q4 2025), $26.2 million (Q3 2025), and $31.9 million (Q2 2025), per Business Quant data.